IDiyas

For the Inventor, By the Inventor

San Antonio, TX, United States of America

Alexander L Weis

USPTO Granted Patents = 18

Average Co-Inventor Count = 2.8

ph-index = 9

Forward Citations = 1,462(Granted Patents)


Location History:

  • Rochester, NY (US) (1991)
  • Berwyn, PA (US) (1993 - 1997)
  • San Antonio, TX (US) (1994 - 2001)

Company Filing History:

goldMedal3 out of 206 
 
Sterling Winthrop Inc.
 patents
silverMedal3 out of 3 
 
Lipitek International, Inc.
 patents
bronzeMedal3 out of 422 
 
Genencor International, Inc.
 patents
4. 3 out of 21,594 
 
Eastman-kodak Company
 patents
5. 2 out of 692 
 
Sterling Drug Inc.
 patents
6. 2 out of 2 
 
Cancer Therapy and Research Center
 patents
7. 1 out of 1,451 
 
Sanofi
 patents
8. 1 out of 1 
 
Lipitek, Inc.
 patent
9. 1 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1991-2001

Loading Chart...
18 patents (USPTO):Explore Patents
1. 6242428 - Nucleoside analogs and uses in treating Plasmodium falciparum infection (2001-06-05),
2. 6207649 - Nucleoside analogs and uses in treating disease (2001-03-27),
3. 6025335 - L-Nucleoside Dimer Compounds and therapeutic uses (2000-02-15),
4. 5939402 - Nucleoside analogs and uses against parasitic infection (1999-08-17),
5. 5885972 - L-pyranosyl nucleosides (1999-03-23),
6. 5677439 - Oligonucleotide analogues containing phosphate diester linkage (1997-10-14),
7. 5672594 - L-erythrosyl nucleosides (1997-09-30),
8. 5604095 - Unsymmetrically linked bisnaphthalimides as antitumor agents (1997-02-18),
9. 5567810 - Nuclease resistant compounds (1996-10-22),
10. 5561042 - Diamine platinum naphthalimide complexes as antitumor agents (1996-10-01),
11. 5559101 - L-ribofuranosyl nucleosides (1996-09-24),
12. 5449691 - 3,4-disubstituted anilines-immunomodulating agents (1995-09-12),
13. 5310760 - 3,4-disubstituted anilines-immunomodulating agents (1994-05-10),
14. 5245022 - Exonuclease resistant terminally substituted oligonucleotides (1993-09-14),
15. 5214134 - Process of linking nucleosides with a siloxane bridge (1993-05-25),

Title: The Innovative Contributions of Alexander L Weis

Introduction

Alexander L Weis is a prominent inventor based in San Antonio, TX (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of nucleoside analogs. With a total of 18 patents to his name, Weis has been instrumental in advancing treatments for various diseases.

Latest Patents

Among his latest patents, Weis has developed innovative nucleoside analogs aimed at treating Plasmodium falciparum infection. This invention focuses on novel nucleosides and nucleoside dimers that contain an L-sugar in at least one of the nucleosides, along with their pharmaceutical compositions. Another notable patent involves pharmaceutical compositions of nucleoside dimers that also contain an L-sugar in at least one of the nucleosides, showcasing his commitment to improving therapeutic options.

Career Highlights

Throughout his career, Weis has worked with reputable companies such as Sterling Winthrop Inc. and Lipitek International, Inc. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research in the pharmaceutical industry.

Collaborations

Weis has collaborated with esteemed colleagues, including Frederick H Hausheer and Charles T Goodhue. These partnerships have fostered a collaborative environment that has led to significant advancements in their respective fields.

Conclusion

Alexander L Weis stands out as a dedicated inventor whose work in nucleoside analogs has the potential to transform treatment options for various diseases. His innovative spirit and collaborative efforts continue to make a lasting impact in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…